AstraZeneca advances its ambition to redefine haematology care with new data from its diverse pipeline and portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and… read more.
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, announced multiple presentations at the upcoming American… read more.
Abbott has initiated a medical device correction for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors in the United States after internal testing determined that some… read more.
Eli Lilly and Company announced that data from studies of Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, will be presented at the… read more.
Rigel Pharmaceuticals Inc. announced a peer-reviewed publication in the Journal of Hematology & Oncology of the final five-year data from the pivotal cohort of the Phase II registrational… read more.
Eli Lilly and Company announced that new data from across its breast oncology portfolio and pipeline will be featured at the San Antonio Breast Cancer Symposium (SABCS), taking… read more.
GE HealthCare announced CE Mark for its StarGuide GX a new digital 4D SPECT/CT system designed with excellent precision, clinical efficiency and impressive versatility. This milestone marks a… read more.
Ono Pharmaceutical Co., Ltd. announced that they received supplemental approval in Japan for Braftovi (encorafenib) capsule in combination with cetuximab, an anti-human EGFR monoclonal antibody, and chemotherapy for… read more.
Edwards Lifesciences announced data demonstrating successful patient outcomes supporting its portfolio of mitral and tricuspid therapies. One-year data from the ENCIRCLE single-arm pivotal trial achieved all primary and… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Paxlovid (nirmatrelvir + ritonavir)…. read more.
Gilead Sciences Inc. announced the Phase III ASCENT-07 study investigating Trodelvy (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer patients did… read more.
NICE(UK): Cabotegravir is recommended as an option for pre-exposure prophylaxis (PrEP) alongside safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults and young… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
